10-Q: Tenon Medical Q3: Revenue Up, Losses Persist, Acquisitions

Tenon Medical reports increased Q3 revenue and gross profit, but ongoing net losses and significant cash burn raise going concern doubts, partially offset by recent acquisitions and a new PIPE financing.

Summary

• Q3 2025 revenue increased 32% to $1.173 million from $0.887 million in Q3 2024.
• Gross profit for Q3 2025 rose 85% to $0.773 million, with gross margin improving to 66% from 47% in Q3 2024.
• Net loss for Q3 2025 was $(3.339) million, compared to $(3.184) million in Q3 2024, indicating increased losses.
• For the nine months ended September 30, 2025, revenue slightly decreased by 2% to $2.463 million from $2.507 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, improved to $(9.724) million from $(10.586) million in the prior year period.
• The company completed the SImmetry and SIMPL acquisitions in August 2025, acquiring assets related to SI Joint fusion systems for a total consideration of $3.127 million, including $0.750 million in cash.
• Cash and cash equivalents decreased to $3.442 million as of September 30, 2025, from $6.535 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, increased to $(8.521) million from $(7.101) million in the prior year.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• A PIPE financing for $2.850 million gross proceeds was announced on November 11, 2025, expected to close on November 14, 2025.

Sentiment

Score: 3

Explanation: While Q3 revenue and gross profit showed improvement, the company continues to report significant net losses, increasing cash burn from operations, and explicitly states substantial doubt about its ability to continue as a going concern. The recent capital raise provides some short-term relief but does not fundamentally alter the underlying financial challenges and operational risks, including ineffective disclosure controls.

Positives

• Q3 2025 revenue increased by 32% year-over-year to $1.173 million, driven by increased surgical procedures and the addition of SImmetry sales.
• Gross profit percentage significantly improved to 66% in Q3 2025 from 47% in Q3 2024, benefiting from increased sales volumes and operating leverage.
• Net loss for the nine months ended September 30, 2025, decreased to $(9.724) million from $(10.586) million in the prior year period.
• The acquisition of SiVantage, Inc. and SIMPL Medical, LLC in August 2025 expands the company's product portfolio in the SI Joint fusion market.
• Successful pricing of a PIPE financing for $2.850 million gross proceeds, expected to close in November 2025, provides much-needed capital.

Negatives

• The company continues to incur significant net losses, with a Q3 2025 net loss of $(3.339) million, an increase from $(3.184) million in Q3 2024.
• Cash and cash equivalents decreased substantially to $3.442 million at September 30, 2025, from $6.535 million at December 31, 2024.
• Net cash used in operating activities increased to $(8.521) million for the nine months ended September 30, 2025, from $(7.101) million in the prior year, indicating a higher cash burn rate.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• Disclosure controls and procedures were deemed not effective at the reasonable assurance level due to insufficient resources for adequate supervision and segregation of duties, representing a material weakness.
• The Equity Line of Credit with Lincoln Park Capital Fund, LLC terminated in September 2025, removing a potential source of capital.

Risks

• Substantial doubt about the company's ability to continue as a going concern for at least twelve months due to accumulated losses and negative cash flows.
• Inability to raise necessary additional capital through public or private equity offerings, debt financings, or collaborations on acceptable terms, or at all.
• Potential dilution of existing stockholders' ownership interest if additional capital is raised through equity offerings.
• Covenants limiting or restricting specific actions if additional capital is raised through debt financing.
• Inability to effectively segregate accounting duties, which constitutes a material weakness in internal controls and renders disclosure controls and procedures not effective.
• Uncertainty of future revenues and potential changes in business strategy, regulatory developments, or R&D spending plans that could consume capital resources more rapidly.

Future Outlook

Management expects to incur additional operating losses and negative cash flows in the foreseeable future as the company continues product development and commercialization of its SI Joint systems. The company plans to raise additional capital through public or private equity offerings, debt financings, and collaborations to fund operations, as existing cash is insufficient for the next twelve months. Operating expenses are expected to increase in absolute dollars with business growth, particularly sales and marketing and R&D, though general and administrative expenses are anticipated to decrease as a percentage of revenue over time.

Management Comments

• "We expect operating expenses to increase in absolute dollars as we continue to invest and grow our business."
• "We expect our sales and marketing expenses to increase in absolute dollars with the increased sales resulting in higher commissions and salaries, increased clinician and sales representative training, and the cost to complete our clinical study to gain wider clinician adoption of our products."
• "We expect research and development expense to increase in absolute dollars as we improve our existing products, develop new products, add research and development personnel, and undergo clinical activities that may be required for regulatory clearances of future products."
• "While we expect the general and administrative expenses to increase in absolute dollars, we anticipate that it will decrease as a percentage of revenue over time."
• "Based upon our current operating plan, our existing cash and cash equivalents will not be sufficient to fund our operating expenses and working capital requirements through at least the next 12 months from the date these financial statements were filed."
• "We plan to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations."
• "Due to the uncertainty in our ability to raise capital, management believes that there is substantial doubt in our ability to continue as a going concern for the next twelve months from the issuance of these condensed financial statements."
• "Our Chief Executive Officer and President and Chief Financial Officer concluded that our disclosure controls and procedures are not effective at the reasonable assurance level."

Industry Context

Tenon Medical operates in the highly competitive medical devices industry, specifically focusing on sacroiliac (SI) joint fusion systems. The recent acquisitions of SImmetry and SIMPL systems indicate a strategy to consolidate and expand its market presence within this niche, leveraging a broader product portfolio to address SI Joint disorders. The company's focus on less invasive approaches aligns with broader trends in medical device innovation towards minimally invasive procedures.

Corporate Governance

Related Party Transactions

• The acquisitions of SiVantage, Inc. and SIMPL Medical, LLC were considered related businesses under common control and treated as a single business acquisition.

Stakeholder Impact

• Shareholders face significant dilution from recent and planned equity raises, ongoing net losses, and substantial doubt about the company's ability to continue as a going concern. Potential for further dilution exists if more capital is raised.
• Employees may experience uncertainty due to the going concern warning, although potential growth from acquisitions could offer some stability.
• Customers benefit from an expanded product portfolio (Catamaran, SImmetry, SIMPL) offering more options for SI Joint disorder treatment.
• Creditors face increased risk due to the going concern warning and the company's reliance on future capital raises to meet its obligations.

Next Steps

• Obtain stockholder approval for the exercisability of Series C-1 and C-2 Warrants within 165 days of the March 11, 2025 inducement transaction.
• Complete the detailed valuation of certain tangible and intangible assets and liabilities related to the SI Acquisition, expected to be finalized within one year of the acquisition date.
• Continue efforts to raise additional capital through public or private equity offerings, debt financings, and collaborations.
• Address the material weakness in internal controls related to insufficient resources for adequate supervision and segregation of duties.
• Complete the clinical study to gain wider clinician adoption of products.
• Improve existing products and develop new products.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by persistent net losses, a rapidly depleting cash balance, and an explicit 'going concern' warning from management. While Q3 revenue growth and gross margin improvement are positive, they are overshadowed by increasing operating cash burn and the fundamental challenge of achieving profitability. The recent PIPE financing provides only a temporary reprieve and comes with significant shareholder dilution. The identified material weakness in internal controls further exacerbates investment risk. Given the high operational risk, continued losses, and reliance on dilutive financing, a seasoned investor would likely recommend selling or avoiding the stock until there is a clear path to sustainable profitability and resolution of the going concern issue.

Keywords

Tenon Medical, TNON, SEC Filing, 10-Q, Quarterly Report, Medical Device, SI Joint Fusion, Catamaran System, SImmetry System, SIMPL Products, Sacroiliac Joint, Financial Results, Net Loss, Revenue Growth, Gross Profit, Cash Flow, Going Concern, Capital Raise, PIPE Financing, Acquisition, Business Combination, Disclosure Controls, Internal Controls, Warrants, Equity Offering